Objective: To explore the molecular mechanisms of Purendan superfine powder(PRD)on metabolic disorder and the protection on macroangiopathy by investigating the protein expression of insulin receptor substrate-1 (IRS-1)

phosphatidylinositol 3-kinase (PI3K)

glucose transporter 4 (GLUT4) and nuclear factor-κB (NF-κB) of skeletal muscles in type 2 diabetes mellitus(T2DM) rats with macroangiopathy. Method: High-fat-diet/streptozotocin (STZ

30 mg·kg-1)-induced type 2 diabetes mellitus rats were developed and treated with PRD (0.885

1.770

3.540 g·kg-1) for four weeks and rosiglitazone (0.36×10-3 g·kg-1) was used as positive control drugs

then western blot assay was used to analyze the protein expression of IRS-1

PI3K

GLUT 4 and NF-κB of skeletal muscle in the rats. Result: The protein expression of IRS-1

PI3K and GLUT-4 was significantly decreased in T2DM group compared with the control group (P<0.01)

while NF-κB expression was significantly increased (P<0.01). After the treatment of PRD

the expression of IRS-1

PI3K and GLUT-4 was up-regulated

and NF-κB was down-regulated significantly (P<0.05 or P<0.01)

which was equivalent to the positive drugs. Conclusion: PRD could improve insulin resistance

decrease blood glucose and fat

protect the vascular endothelium injury by up-regulating IRS-1

PI-3K and GLUT 4 protein expression and down-regulating NF-κB protein expression of skeletal muscle in T2DM rats.